Equities

Caplin Point Laboratories Ltd

CAPLIPOINT:NSI

Caplin Point Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,011.80
  • Today's Change-94.15 / -4.47%
  • Shares traded127.54k
  • 1 Year change+82.98%
  • Beta0.6513
Data delayed at least 15 minutes, as of Nov 08 2024 10:19 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments7,8076,4365,087
Total Receivables, Net7,3685,6264,371
Total Inventory3,6302,8822,273
Prepaid expenses18----
Other current assets, total1066001,248
Total current assets18,92915,54512,978
Property, plant & equipment, net5,5684,8942,935
Goodwill, net28280.50
Intangibles, net9884108
Long term investments1,376709632
Note receivable - long term18235--
Other long term assets523825
Total assets26,98121,91417,363
LIABILITIES
Accounts payable2,0941,6441,632
Accrued expenses2538598
Notes payable/short-term debt000
Current portion long-term debt/capital leases11469.60
Other current liabilities, total955906337
Total current liabilities3,3132,6802,077
Total long term debt9.209.3012
Total debt205521
Deferred income tax----24
Minority interest311268260
Other liabilities, total191152152
Total liabilities3,8243,1092,524
SHAREHOLDERS EQUITY
Common stock152152152
Additional paid-in capital154134146
Retained earnings (accumulated deficit)19,77215,54312,055
Treasury stock - common------
Unrealized gain (loss)746746746
Other equity, total2,1912,0771,651
Total equity23,15718,80514,839
Total liabilities & shareholders' equity26,98121,91417,363
Total common shares outstanding767676
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.